Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Depreciation & Amortization (CF) (2016 - 2025)

Wave Life Sciences' Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $804000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 11.36% year-over-year to $804000.0; the TTM value through Dec 2025 reached $3.4 million, down 12.73%, while the annual FY2025 figure was $3.4 million, 12.73% down from the prior year.
  • Depreciation & Amortization (CF) reached $804000.0 in Q4 2025 per WVE's latest filing, down from $856000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q1 2021 to a low of $804000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $1.3 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): dropped 4.46% in 2021, then fell 29.71% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.8 million in 2021, then dropped by 13.55% to $1.5 million in 2022, then dropped by 29.71% to $1.1 million in 2023, then decreased by 16.1% to $907000.0 in 2024, then fell by 11.36% to $804000.0 in 2025.
  • Per Business Quant, the three most recent readings for WVE's Depreciation & Amortization (CF) are $804000.0 (Q4 2025), $856000.0 (Q3 2025), and $865000.0 (Q2 2025).